• LAST PRICE
    59.6950
  • TODAY'S CHANGE (%)
    Trending Up0.3650 (0.6152%)
  • Bid / Lots
    59.5900/ 6
  • Ask / Lots
    59.9100/ 6
  • Open / Previous Close
    59.8200 / 59.3300
  • Day Range
    Low 59.2601
    High 59.9500
  • 52 Week Range
    Low 19.0500
    High 62.4000
  • Volume
    46,115
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 59.33
TimeVolumeRVMD
09:32 ET926759.27
09:33 ET191859.38
09:35 ET36659.5175
09:37 ET51659.75
09:39 ET362259.71
09:42 ET70059.88
09:44 ET242159.75
09:46 ET212359.71
09:48 ET169759.895
09:50 ET38059.8882
09:51 ET60059.75
09:53 ET192359.695
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRVMD
Revolution Medicines Inc
10.0B
-16.6x
---
United StatesPCVX
Vaxcyte Inc
12.4B
-22.0x
---
United StatesMDGL
Madrigal Pharmaceuticals Inc
7.4B
-13.3x
---
United StatesVKTX
Viking Therapeutics Inc
6.8B
-64.0x
---
United StatesITCI
Intra-Cellular Therapies Inc
9.4B
-103.3x
---
United StatesCYTK
Cytokinetics Inc
6.6B
-10.7x
---
As of 2024-11-13

Company Information

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Contact Information

Headquarters
700 Saginaw DrREDWOOD CITY, CA, United States 94063-4752
Phone
415-766-3638
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith
Chief Financial Officer
Jack Anders
President - Research and Development
Steve Kelsey
Chief Operating Officer
Margaret Horn
Executive Vice President - Development
Xiaolin Wang

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$10.0B
Revenue (TTM)
$742.0K
Shares Outstanding
168.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.41
EPS
$-3.59
Book Value
$11.09
P/E Ratio
-16.6x
Price/Sales (TTM)
13,450.8
Price/Cash Flow (TTM)
---
Operating Margin
-88,409.30%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.